Table 2.
∆HMGB1 and correlations with disease and patient outcome factors
| N (%) | ∆HMGB1 (ln mean ± SEM), ng/ml |
R | P* | |
|---|---|---|---|---|
| Thrombocytesa | 49 (98) | 0.21 | 0.16 | |
| Lymphocytesa | 47 (94) | 0.12 | 0.43 | |
| Neutrophilsa | 49 (98) | 0.069 | 0.63 | |
| Monocytesa | 46 (92) | 0.30 | 0.040 | |
| Lactate dehydrogenasea | 48 (96) | 0.035 | 0.81 | |
| Erythrocyte sedimentation ratea | 42 (84) | –0.010 | 0.95 | |
| Albumina | 49 (98) | –0.058 | 0.69 | |
| ∆VNACT | 42 (84) | 0.014 | 0.93 | |
| ypT stage | ||||
| 0–2 | 28 (56) | 0.21 ± 0.15 | ||
| 3–4 | 19 (38) | 0.07 ± 0.17 | 0.53 | |
| ypN stage | ||||
| 0 | 36 (72) | 0.21 ± 0.13 | ||
| 1–2 | 12 (24) | –0.02 ± 0.21 | 0.37 | |
| DMFS | ||||
| No event | 36 (72) | 0.27 ± 0.12 | ||
| Event | 13 (26) | –0.23 ± 0.20 | 0.041 | |
| OS | ||||
| No event | 42 (84) | 0.26 ± 0.11 | ||
| Event | 7 (14) | –0.60 ± 0.25 | 0.005 | |
| OS among cases with DMFS eventb | ||||
| No event | 6 (12) | 0.19 ± 0.25 | ||
| Event | 7 (14) | –0.60 ± 0.25 | 0.048 |
*By Pearson correlation test or independent sample t-test
aAlteration during the neoadjuvant chemotherapy
bCases with DMFS event were analyzed for OS